the output will be able to produce measurements of great sensitivity and precision.
Finally, we note that at present, application of sensitive molecular detection methods in the developing world, as well as in the developed world, including detection of common infectious disease and routine health assessment via serum proteomics, will be made difficult by the cost and difficulty of aggregating licenses to existing patents covering the different steps of the methods. It may also be hampered by a need to operate through an existing industrial structure that favors application of molecular diagnostic methods to perceived higher-return applications such as diagnosis of cancer and chronic diseases of affluent countries. Widespread application of sensitive molecular detection methods to other applications may require modification of licensing frameworks to facilitate aggregation of intellectual property to combine the experimental steps. It may also require deliberate attention to the creation of a modified industrial structure that allows profitable (or subsidized) deployment of these methods at lower price points.
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